Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

A systematic review of reported cost for smear and culture tests during multidrug-resistant tuberculosis treatment.

Lu C, Liu Q, Sarma A, Fitzpatrick C, Falzon D, Mitnick CD.

PLoS One. 2013;8(2):e56074. doi: 10.1371/journal.pone.0056074. Epub 2013 Feb 15. Review.

2.

Costs to Health Services and the Patient of Treating Tuberculosis: A Systematic Literature Review.

Laurence YV, Griffiths UK, Vassall A.

Pharmacoeconomics. 2015 Sep;33(9):939-55. doi: 10.1007/s40273-015-0279-6. Review.

3.

Cost-effectiveness of treating multidrug-resistant tuberculosis.

Resch SC, Salomon JA, Murray M, Weinstein MC.

PLoS Med. 2006 Jul;3(7):e241.

4.

Are we justified in treating for multidrug-resistant tuberculosis based on positive follow-up smear results?

Kumar RS, Kumar AM, Claassens M, Banurekha VV, Sekar G, Venkatesan P, Swaminathan S.

Int J Tuberc Lung Dis. 2014 Apr;18(4):449-53. doi: 10.5588/ijtld.13.0429.

PMID:
24670701
5.

Is introducing rapid culture into the diagnostic algorithm of smear-negative tuberculosis cost-effective?

Yakhelef N, Audibert M, Varaine F, Chakaya J, Sitienei J, Huerga H, Bonnet M.

Int J Tuberc Lung Dis. 2014 May;18(5):541-6. doi: 10.5588/ijtld.13.0630.

PMID:
24903790
6.

Stepwise implementation of a new diagnostic algorithm for multidrug-resistant tuberculosis in Haiti.

Gauthier M, Somoskövi A, Berland JL, Ocheretina O, Mabou MM, Boncy J, Gutierrez C, Vernet G, Pape JW.

Int J Tuberc Lung Dis. 2014 Feb;18(2):220-6. doi: 10.5588/ijtld.13.0513.

PMID:
24429317
7.

Frequency and type of microbiological monitoring of multidrug-resistant tuberculosis treatment.

Kurbatova EV, Gammino VM, Bayona J, Becerra M, Danilovitz M, Falzon D, Gelmanova I, Keshavjee S, Leimane V, Mitnick CD, Quelapio MI, Riekstina V, Taylor A, Viiklepp P, Zignol M, Cegielski JP.

Int J Tuberc Lung Dis. 2011 Nov;15(11):1553-5, i. doi: 10.5588/ijtld.11.0101.

PMID:
22008772
8.

Cost of multi drug resistance tuberculosis in Germany.

Diel R, Nienhaus A, Lampenius N, Rüsch-Gerdes S, Richter E.

Respir Med. 2014 Nov;108(11):1677-87. doi: 10.1016/j.rmed.2014.09.021. Epub 2014 Oct 15.

9.

A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis.

Fitzpatrick C, Floyd K.

Pharmacoeconomics. 2012 Jan;30(1):63-80. doi: 10.2165/11595340-000000000-00000. Review. Erratum in: Pharmacoeconomics. 2012 Jan;30(1):81.

PMID:
22070215
10.

Point-of-care Xpert® MTB/RIF for smear-negative tuberculosis suspects at a primary care clinic in South Africa.

Van Rie A, Page-Shipp L, Hanrahan CF, Schnippel K, Dansey H, Bassett J, Clouse K, Scott L, Stevens W, Sanne I.

Int J Tuberc Lung Dis. 2013 Mar;17(3):368-72. doi: 10.5588/ijtld.12.0392.

11.

Cost and cost-effectiveness of multidrug-resistant tuberculosis treatment in Estonia and Russia.

Floyd K, Hutubessy R, Kliiman K, Centis R, Khurieva N, Jakobowiak W, Danilovits M, Peremitin G, Keshavjee S, Migliori GB.

Eur Respir J. 2012 Jul;40(1):133-42. doi: 10.1183/09031936.00169411. Epub 2012 Feb 23.

12.
13.

Patient and family costs associated with tuberculosis, including multidrug-resistant tuberculosis, in Ecuador.

Rouzier VA, Oxlade O, Verduga R, Gresely L, Menzies D.

Int J Tuberc Lung Dis. 2010 Oct;14(10):1316-22.

PMID:
20843424
14.

Controlling multidrug-resistant tuberculosis and access to expensive drugs: a rational framework.

Pablos-Mendez A, Gowda DK, Frieden TR.

Bull World Health Organ. 2002;80(6):489-95; discussion 495-500.

15.

Predictors of delayed culture conversion in patients treated for multidrug-resistant tuberculosis in Pakistan.

Qazi F, Khan U, Khowaja S, Javaid M, Ahmed A, Salahuddin N, Hussain H, Becerra MC, Golub JE, Khan AJ.

Int J Tuberc Lung Dis. 2011 Nov;15(11):1556-9, i. doi: 10.5588/ijtld.10.0679.

PMID:
22008773
16.

Association between Regimen Composition and Treatment Response in Patients with Multidrug-Resistant Tuberculosis: A Prospective Cohort Study.

Yuen CM, Kurbatova EV, Tupasi T, Caoili JC, Van Der Walt M, Kvasnovsky C, Yagui M, Bayona J, Contreras C, Leimane V, Ershova J, Via LE, Kim H, Akksilp S, Kazennyy BY, Volchenkov GV, Jou R, Kliiman K, Demikhova OV, Vasilyeva IA, Dalton T, Cegielski JP.

PLoS Med. 2015 Dec 29;12(12):e1001932. doi: 10.1371/journal.pmed.1001932. eCollection 2015 Dec.

17.

Chinese herbal medicine as adjuvant treatment to chemotherapy for multidrug-resistant tuberculosis (MDR-TB): A systematic review of randomised clinical trials.

Wang M, Guan X, Chi Y, Robinson N, Liu JP.

Tuberculosis (Edinb). 2015 Jul;95(4):364-72. doi: 10.1016/j.tube.2015.03.003. Epub 2015 Mar 18. Review.

PMID:
25861717
18.

Cost-effectiveness of rapid susceptibility testing against second-line drugs for tuberculosis.

Dowdy DW, van't Hoog A, Shah M, Cobelens F.

Int J Tuberc Lung Dis. 2014 Jun;18(6):647-54. doi: 10.5588/ijtld.13.0776.

PMID:
24903933
19.

Costs of inpatient treatment for multi-drug-resistant tuberculosis in South Africa.

Schnippel K, Rosen S, Shearer K, Martinson N, Long L, Sanne I, Variava E.

Trop Med Int Health. 2013 Jan;18(1):109-16. doi: 10.1111/tmi.12018. Epub 2012 Nov 21.

20.

The impact and cost-effectiveness of strategies to detect drug-resistant tuberculosis.

Oxlade O, Falzon D, Menzies D.

Eur Respir J. 2012 Mar;39(3):626-34. doi: 10.1183/09031936.00065311. Epub 2011 Aug 4.

Supplemental Content

Support Center